within Pharmacolibrary.Drugs.ATC.L;

model L01EX25
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.39,
    Cl             = 0.0012150000000000002,
    adminDuration  = 600,
    adminMass      = 800 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.116,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.007,
    Tlag           = 10.200000000000001,            
    Vdp             = 0.363,
    k12             = 76.2,
    k21             = 76.2
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01EX25</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Umbralisib is an oral, selective phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor with additional inhibition of casein kinase 1 epsilon (CK1ε). It is used for the treatment of certain B-cell malignancies, including marginal zone lymphoma and follicular lymphoma. It was approved by the FDA but was voluntarily withdrawn from the market in 2022 due to safety concerns.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters as observed in adult cancer patients receiving oral umbralisib as a single agent.</p><h4>References</h4><ol><li><p>Dhillon, S, &amp; Keam, SJ (2021). Umbralisib: First Approval. <i>Drugs</i> 81(7) 857–866. DOI:<a href=&quot;https://doi.org/10.1007/s40265-021-01504-2&quot;>10.1007/s40265-021-01504-2</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33797740/&quot;>https://pubmed.ncbi.nlm.nih.gov/33797740</a></p></li><li><p>Weng, Q, et al., &amp; Zhang, P (2022). Effect of Sophocarpine on the Pharmacokinetics of Umbralisib in Rat Plasma Using a Novel UPLC-MS/MS Method. <i>Frontiers in pharmacology</i> 13 749095–None. DOI:<a href=&quot;https://doi.org/10.3389/fphar.2022.749095&quot;>10.3389/fphar.2022.749095</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35126158/&quot;>https://pubmed.ncbi.nlm.nih.gov/35126158</a></p></li><li><p>Burris, HA, et al., &amp; O&#x27;Connor, OA (2018). Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study. <i>The Lancet. Oncology</i> 19(4) 486–496. DOI:<a href=&quot;https://doi.org/10.1016/S1470-2045(18)30082-2&quot;>10.1016/S1470-2045(18)30082-2</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29475723/&quot;>https://pubmed.ncbi.nlm.nih.gov/29475723</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01EX25;
